-
FDA Approves Bexlutry (lutetium Lu 177 dotatate) for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults
Boston, MA – 14 September, 2026 – Curium™ announced today that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection for the treatment of… Source: Read More
-
FDA Approves Bravnetsa (lutetium Lu 177 dotatate) as a Therapeutic Equivalent to Lutathera for the Treatment of Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors in Adults
NASDAQ: $LNTH BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver… Source: Read More